STROBE Statement—Checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract Title: retrospective descriptive study
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found Page 2, lines 28-41
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 3, lines 48-61
Objectives	3	State specific objectives, including any prespecified hypotheses Page 3, lines 62-66
Methods		
Study design	4	Present key elements of study design early in the paper Page 5, lines 94-121
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 4, lines 70-92
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants Page 5, lines 97-99 & lines 104-107
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 5-6, lines 97-130
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 5-6, lines 97-130
Bias	9	Describe any efforts to address potential sources of bias Page 5-6, lines 97-130
Study size	10	Explain how the study size was arrived at Page 5-6, lines 97-99 & 104-107
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why There are no quantitative variables
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding Page 6, lines 123-130
		(*b*) Describe any methods used to examine subgroups and interactions Page 6, lines 123-130
		(*c*) Explain how missing data were addressed Page 5, lines 105-107
		(*d*) If applicable, describe analytical methods taking account of sampling strategy Not applicable.
		(*e*) Describe any sensitivity analyses

		Not applicable.
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 6-7, lines 134-135, 151-152
		(b) Give reasons for non-participation at each stage Refer to exclusion criteria.
		(c) Consider use of a flow diagram A flow diagram is included.
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 7, 146-150; Table 1.
		(b) Indicate number of participants with missing data for each variable of interest As data was obtained through chart reviews, there were no missing data for socio-demographic characteristics, and missing information were categorised as "No" for symptoms, as specified in the Methods section Page 6, line 128.
Outcome data	15*	Report numbers of outcome events or summary measures Lines 126-144
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Lines 147-150
		(*b*) Report category boundaries when continuous variables were categorized Table 1 (age).
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not applicable, descriptive study only.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Not applicable
Discussion		
Key results	18	Summarise key results with reference to study objectives Page 8, lines 175-182
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Lines 213-243
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Lines 175-252
Generalisability	21	Discuss the generalisability (external validity) of the study results Lines 242-243
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Page 1, lines 15-17

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.